{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:03:41Z","timestamp":1790805821069,"version":"4.1.0"},"reference-count":280,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230058"],"award-info":[{"award-number":["82230058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011176","name":"Peking Union Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.semcancer.2025.05.009","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T13:09:33Z","timestamp":1746796173000},"page":"39-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Metabolic reprogramming in cancer therapy-related cardiovascular toxicity: Mechanisms and intervention strategies"],"prefix":"10.1016","volume":"113","author":[{"given":"Cheng","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-1902","authenticated-orcid":false,"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10159","key":"10.1016\/j.semcancer.2025.05.009_bib1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib2","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib3","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.semcancer.2025.05.009_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1055\/s-0041-1729885","article-title":"The growing impact of cardiovascular oncology: epidemiology and pathophysiology","volume":"47","author":"Tufano","year":"2021","journal-title":"Semin Thromb. Hemost."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamacardio.2016.3841","article-title":"A population-based study of cardiovascular mortality following early-stage breast cancer","volume":"2","author":"Abdel-Qadir","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"12","key":"10.1016\/j.semcancer.2025.05.009_bib6","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.2013.51.1055","article-title":"Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study","volume":"32","author":"Armstrong","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.semcancer.2025.05.009_bib7","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"41","key":"10.1016\/j.semcancer.2025.05.009_bib8","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tcm.2018.06.001","article-title":"Update on cardio-oncology: novel cancer therapeutics and associated cardiotoxicities","volume":"29","author":"Guha","year":"2019","journal-title":"Trends Cardiovasc Med."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41569-022-00698-6","article-title":"Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer","volume":"19","author":"Karlstaedt","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"issue":"9","key":"10.1016\/j.semcancer.2025.05.009_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","article-title":"Cardiovascular disease and cancer: shared risk factors and mechanisms","volume":"21","author":"Wilcox","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"issue":"9","key":"10.1016\/j.semcancer.2025.05.009_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132747","article-title":"Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity","volume":"5","author":"Tadokoro","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12944-024-02002-6","article-title":"Lipid changes during endocrine therapy in early-stage breast cancer patients: a real-world study","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.semcancer.2025.05.009_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920925991","article-title":"Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study","volume":"12","author":"Wang","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib17","article-title":"Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis","volume":"10","author":"Zhang","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","article-title":"Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression","volume":"73","author":"Li","year":"2016","journal-title":"Cell Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrc.2016.77","article-title":"Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?","volume":"16","author":"Hay","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051056","article-title":"Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation","volume":"10","author":"Schiliro","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.semcancer.2025.05.009_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117257","article-title":"Reprogramming of glucose metabolism: the hallmark of malignant transformation and target for advanced diagnostics and treatments","volume":"178","author":"Tang","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.semcancer.2025.05.009_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104511","article-title":"Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy","volume":"150","author":"Abdel-Wahab","year":"2019","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.semcancer.2025.05.009_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2022.11.007","article-title":"Role of LDH in tumor glycolysis: regulation of LDHA by small molecules for cancer therapeutics","volume":"87","author":"Sharma","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4149\/neo_2020_200530N584","article-title":"PGC-1\u03b1 activates SIRT3 to modulate cell proliferation and glycolytic metabolism in breast cancer","volume":"68","author":"Zu","year":"2021","journal-title":"Neoplasma"},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1158\/0008-5472.CAN-21-1259","article-title":"CircRPN2 inhibits aerobic glycolysis and metastasis in hepatocellular carcinoma","volume":"82","author":"Li","year":"2022","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2025.05.009_bib28","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.69223","article-title":"GFPT2\/GFAT2 and AMDHD2 act in tandem to control the hexosamine pathway","volume":"11","author":"Kroef","year":"2022","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12265-023-10432-3","article-title":"Cardiac metabolism, reprogramming, and diseases","volume":"17","author":"Wang","year":"2024","journal-title":"J. Cardiovasc Transl. Res."},{"issue":"7 Pt B","key":"10.1016\/j.semcancer.2025.05.009_bib30","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.bbamcr.2016.02.011","article-title":"Hypoxia-driven glycolytic and fructolytic metabolic programs: pivotal to hypertrophic heart disease","volume":"1863","author":"Mirtschink","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.semcancer.2025.05.009_bib31","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41419-022-05403-6","article-title":"MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis","volume":"13","author":"Zou","year":"2022","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib32","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1007\/s10753-020-01255-4","article-title":"Overexpression of peroxisome proliferator-activated receptor \u03b3 coactivator 1-\u03b1 protects cardiomyocytes from lipopolysaccharide-induced mitochondrial damage and apoptosis","volume":"43","author":"Zhang","year":"2020","journal-title":"Inflammation"},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MOL.0000000000000337","article-title":"Notch, lipids, and endothelial cells","volume":"27","author":"Briot","year":"2016","journal-title":"Curr. Opin. Lipido"},{"issue":"8","key":"10.1016\/j.semcancer.2025.05.009_bib34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tem.2017.05.004","article-title":"AMPK as a therapeutic target for treating metabolic diseases","volume":"28","author":"Day","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib35","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ehf2.14311","article-title":"MicroRNA-494 regulates high glucose-induced cardiomyocyte apoptosis and autophagy by PI3K\/AKT\/mTOR signalling pathway","volume":"10","author":"Ning","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s43018-023-00702-z","article-title":"Lipids as mediators of cancer progression and metastasis","volume":"5","author":"Vogel","year":"2024","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12672-025-02044-x","article-title":"Integrated bulk and single-cell transcriptomic analysis unveiled a novel cuproptosis-related lipid metabolism gene molecular pattern and a risk index for predicting prognosis and antitumor drug sensitivity in breast cancer","volume":"16","author":"Zeng","year":"2025","journal-title":"Discov. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.05.009_bib38","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.cmet.2024.06.003","article-title":"Human cardiac metabolism","volume":"36","author":"Bornstein","year":"2024","journal-title":"Cell Metab."},{"issue":"4746","key":"10.1016\/j.semcancer.2025.05.009_bib39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2025.05.009_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-19-1592-5_7","article-title":"ABCA1, ABCG1, and cholesterol homeostasis","volume":"1377","author":"Yu","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2022.106698","article-title":"Lipoxin and glycation in SREBP signaling: insight into diabetic cardiomyopathy and associated lipotoxicity","volume":"164","author":"Thakur","year":"2023","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12010143","article-title":"Sphingolipids and atherosclerosis: the dual role of ceramide and sphingosine-1-phosphate","volume":"12","author":"Piccoli","year":"2023","journal-title":"Antioxidants"},{"issue":"12","key":"10.1016\/j.semcancer.2025.05.009_bib43","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"14","key":"10.1016\/j.semcancer.2025.05.009_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21144987","article-title":"AMPK, mitochondrial function, and cardiovascular disease","volume":"21","author":"Wu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.semcancer.2025.05.009_bib45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","article-title":"Glutamine addiction: a new therapeutic target in cancer","volume":"35","author":"Wise","year":"2010","journal-title":"Trends Biochem Sci."},{"issue":"11","key":"10.1016\/j.semcancer.2025.05.009_bib46","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1080\/15548627.2022.2062875","article-title":"Glutamine, MTOR and autophagy: a multiconnection relationship","volume":"18","author":"Bodineau","year":"2022","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41392-023-01569-3","article-title":"Amino acid metabolism in health and disease","volume":"8","author":"Ling","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"12","key":"10.1016\/j.semcancer.2025.05.009_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/nu13124503","article-title":"Arginine and Arginases modulate metabolism, tumor microenvironment and prostate cancer progression","volume":"13","author":"Matos","year":"2021","journal-title":"Nutrients"},{"issue":"14","key":"10.1016\/j.semcancer.2025.05.009_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143541","article-title":"Arginine signaling and cancer metabolism","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.semcancer.2025.05.009_bib50","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1007\/s00018-021-03828-4","article-title":"Arginine-dependent immune responses","volume":"78","author":"Mart\u00ed I L\u00edndez","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib51","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12672-024-01544-6","article-title":"Understanding serine and glycine metabolism in cancer: a path towards precision medicine to improve patient's outcomes","volume":"15","author":"Sanchez-Castillo","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib52","article-title":"Disrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1","author":"Lin","year":"2024","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib53","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/08830185.2021.1954638","article-title":"Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system","volume":"41","author":"Ala","year":"2022","journal-title":"Int. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41569-022-00760-3","article-title":"Branched-chain amino acids in cardiovascular disease","volume":"20","author":"McGarrah","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/mnfr.201300033","article-title":"Arginine and nitric oxide synthase: regulatory mechanisms and cardiovascular aspects","volume":"58","author":"Lorin","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.semcancer.2025.05.009_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1716701","article-title":"Multifarious beneficial effect of nonessential amino acid, glycine: a review","volume":"2017","author":"Razak","year":"2017","journal-title":"Oxid. Med. Cell Longev."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002621","article-title":"Plasma glycine and risk of acute myocardial infarction in patients with suspected stable angina pectoris","volume":"5","author":"Ding","year":"2015","journal-title":"J. Am. Heart Assoc."},{"issue":"12","key":"10.1016\/j.semcancer.2025.05.009_bib58","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s44161-024-00575-0","article-title":"Glutamine-glutamate imbalance in the pathogenesis of cardiovascular disease","volume":"3","author":"Liu","year":"2024","journal-title":"Nat. Cardiovasc Res."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib59","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib60","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.005910","article-title":"Anthracycline cardiotoxicity","volume":"12","author":"Narezkina","year":"2019","journal-title":"Circ. Heart Fail"},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib61","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology State-of-the-Art Review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib62","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1042\/CS20200301","article-title":"Molecular mechanisms of anthracycline cardiovascular toxicity","volume":"135","author":"Narezkina","year":"2021","journal-title":"Clin. Sci. (Lond. )"},{"issue":"14","key":"10.1016\/j.semcancer.2025.05.009_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.05.039","article-title":"Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity","volume":"186","author":"Lei","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2025.05.009_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110028","article-title":"Doxorubicin induced cardio toxicity through sirtuins mediated mitochondrial disruption","volume":"365","author":"Ahmad","year":"2022","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.semcancer.2025.05.009_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1521020","article-title":"Oxidative stress and cellular response to doxorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity","volume":"2017","author":"Cappetta","year":"2017","journal-title":"Oxid. Med. Cell Longev."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.semcancer.2025.05.009_bib67","article-title":"Relevance of ferroptosis to cardiotoxicity caused by anthracyclines: mechanisms to target treatments","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"10.1016\/j.semcancer.2025.05.009_bib68","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.freeradbiomed.2023.06.004","article-title":"Activation of AMPK\u03b12 attenuated doxorubicin-induced cardiotoxicity via inhibiting lipid peroxidation associated ferroptosis","volume":"205","author":"Liao","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12964-023-01077-5","article-title":"Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy","volume":"21","author":"Shi","year":"2023","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib70","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13046-020-01595-x","article-title":"TFEB-NF-\u03baB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity","volume":"39","author":"Wang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib71","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41418-019-0372-z","article-title":"FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT","volume":"27","author":"Zhang","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.semcancer.2025.05.009_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2024.107324","article-title":"Unravelling the metabolic rewiring in the context of doxorubicin-induced cardiotoxicity: fuel preference changes from fatty acids to glucose oxidation","volume":"155","author":"Guerra","year":"2024","journal-title":"Vasc. Pharm."},{"key":"10.1016\/j.semcancer.2025.05.009_bib73","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semcancer.2024.09.003","article-title":"Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: mechanisms and therapeutic implications","volume":"106-107","author":"Yang","year":"2024","journal-title":"Semin Cancer Biol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib74","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/path.5192","article-title":"Doxorubicin-induced cardiotoxicity involves IFN\u03b3-mediated metabolic reprogramming in cardiomyocytes","volume":"247","author":"Ni","year":"2019","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib75","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.semcancer.2025.05.009_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122361","article-title":"Melatonin prevents overproduction of reactive oxygen species and vascular dysfunction induced by cyclophosphamide","volume":"338","author":"Pimenta","year":"2024","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib77","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00204-021-03204-y","article-title":"Cardiotoxicity of cyclophosphamide's metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes","volume":"96","author":"Dion\u00edsio","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119607","article-title":"Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies","volume":"277","author":"Kim","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib79","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12933-017-0604-9","article-title":"Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes","volume":"16","author":"Karam","year":"2017","journal-title":"Cardiovasc Diabetol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.05.009_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23783","article-title":"The effects of berberine and curcumin on cardiac, lipid profile and fibrosis markers in cyclophosphamide-induced cardiac damage: the role of the TRPM2 channel","volume":"38","author":"Huyut","year":"2024","journal-title":"J. Biochem Mol. Toxicol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib81","first-page":"3","article-title":"Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents","volume":"2","author":"Morbidelli","year":"2016","journal-title":"Cardiooncology"},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1108","article-title":"Cisplatin cycles treatment sustains cardiovascular and renal damage involving TLR4 and NLRP3 pathways","volume":"11","author":"Gonz\u00e1lez","year":"2023","journal-title":"Pharm. Res. Perspect."},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib83","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12012-021-09636-3","article-title":"The effect of curcumin nanoparticles on cisplatin-induced cardiotoxicity in male wistar albino rats","volume":"21","author":"Khadrawy","year":"2021","journal-title":"Cardiovasc Toxicol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib84","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","article-title":"Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies","volume":"650","author":"El-Awady","year":"2011","journal-title":"Eur. J. Pharm."},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib85","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib86","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors","volume":"2","author":"Ferrara","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2025.05.009_bib87","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/17425255.2020.1787986","article-title":"Cardiovascular toxicity induced by anti-VEGF\/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management","volume":"16","author":"Jiang","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib88","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","article-title":"Bevacizumab-induced hypertension: clinical presentation and molecular understanding","volume":"182","author":"Li","year":"2018","journal-title":"Pharm. Ther."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","article-title":"HER2+\u2009breast cancer treatment and cardiotoxicity: monitoring and management","volume":"177","author":"Jerusalem","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.semcancer.2025.05.009_bib90","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.2147\/DDDT.S469331","article-title":"Cardiotoxicity of anticancer drugs: molecular mechanisms, clinical management and innovative treatment","volume":"18","author":"Gao","year":"2024","journal-title":"Drug Des. Devel Ther."},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib91","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib92","first-page":"1","article-title":"[Cardiotoxicity from anti-HER-2 therapies in patients with HER-2 positive breast cancer]","volume":"62","author":"Camejo-Martinez","year":"2024","journal-title":"Rev. Med. Inst. Mex. Seguro Soc."},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib93","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2174\/1568009618666171129222159","article-title":"Toxicology of trastuzumab: an insight into mechanisms of cardiotoxicity","volume":"19","author":"An","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"issue":"11","key":"10.1016\/j.semcancer.2025.05.009_bib94","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11912-021-01114-x","article-title":"Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer","volume":"23","author":"Dent","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.semcancer.2025.05.009_bib95","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.freeradbiomed.2023.06.019","article-title":"Trastuzumab-induced cardiomyopathy via ferroptosis-mediated mitochondrial dysfunction","volume":"206","author":"Ye","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib96","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/cas.15508","article-title":"Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity","volume":"113","author":"Sasaki","year":"2022","journal-title":"Cancer Sci."},{"issue":"16","key":"10.1016\/j.semcancer.2025.05.009_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16162869","article-title":"Profiling the cardiovascular toxicities of CDK4\/6 inhibitors: a real-world pharmacovigilance study","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2025.05.009_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104296","article-title":"Cardiovascular complications of ribociclib in breast cancer patients","volume":"196","author":"Fiste","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"18","key":"10.1016\/j.semcancer.2025.05.009_bib99","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for hr-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000519728","article-title":"Second-degree type 2 atrioventricular block requiring permanent cardiac pacing in patients on CDK4\/6 inhibitors: report of two cases","volume":"17","author":"Cicini","year":"2022","journal-title":"Breast Care"},{"key":"10.1016\/j.semcancer.2025.05.009_bib101","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and cardiotoxic events in breast cancer: a pharmacovigilance study based on the FAERS database","author":"Li","year":"2024","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib102","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40259-019-00382-1","article-title":"Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications","volume":"33","author":"Santoni","year":"2019","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.semcancer.2025.05.009_bib103","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib104","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11886-023-01845-2","article-title":"Cardiovascular toxicities associated with tyrosine kinase inhibitors","volume":"25","author":"Sayegh","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"21","key":"10.1016\/j.semcancer.2025.05.009_bib106","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","article-title":"Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC State-of-the-Art review","volume":"77","author":"Rao","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib107","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib108","doi-asserted-by":"crossref","DOI":"10.1042\/CS20200305","article-title":"Cardiotoxic effects of angiogenesis inhibitors","volume":"135","author":"Dobbin","year":"2021","journal-title":"Clin. Sci. (Lond. )"},{"issue":"20","key":"10.1016\/j.semcancer.2025.05.009_bib109","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib110","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3389\/fphar.2020.00891","article-title":"A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors","volume":"11","author":"Jin","year":"2020","journal-title":"Front. Pharm."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib111","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib112","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.semcancer.2025.05.009_bib113","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMc1108849","article-title":"Reversible cardiomyopathy associated with sunitinib and sorafenib","volume":"365","author":"Uraizee","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2025.05.009_bib114","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ejca.2014.05.013","article-title":"Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events","volume":"50","author":"Ewer","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jacbts.2018.01.011","article-title":"Exaggerated cardiotoxicity of sunitinib in stressed 3-dimensional heart muscles","volume":"3","author":"Eschenhagen","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib116","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/phar.2896","article-title":"Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors","volume":"44","author":"Yuan","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.semcancer.2025.05.009_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108256","article-title":"Recent advances in metabolism and toxicity of tyrosine kinase inhibitors","volume":"237","author":"Zhao","year":"2022","journal-title":"Pharm. Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib118","first-page":"35","article-title":"Investigating cardiovascular diseases related to endocrine therapy in hormone receptor-positive early breast cancer: insights from a nationwide real-world study","volume":"11","author":"Zeng","year":"2025","journal-title":"Cardio-Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.05.009_bib119","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","article-title":"Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study","volume":"141","author":"Khosrow-Khavar","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdw673","article-title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Khosrow-Khavar","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111680","article-title":"The effect of tamoxifen on the lipid profile in women: A systematic review and meta-analysis of randomized controlled trials","volume":"159","author":"Alomar","year":"2022","journal-title":"Exp. Gerontol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.05.009_bib122","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/annonc\/mdq707","article-title":"The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study","volume":"22","author":"Hozumi","year":"2011","journal-title":"Ann. Oncol."},{"issue":"10021","key":"10.1016\/j.semcancer.2025.05.009_bib123","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(15)01168-X","article-title":"Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Margolese","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib124","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12905-023-02855-6","article-title":"Thrombosis of acute superior mesenteric artery in a patient with breast cancer receiving toremifene therapy: a case report and literature review","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Women\u2019s. Health"},{"key":"10.1016\/j.semcancer.2025.05.009_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115969","article-title":"The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer","volume":"170","author":"Buijs","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.semcancer.2025.05.009_bib126","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.breast.2021.07.004","article-title":"Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: a population-based cohort study","volume":"59","author":"Sund","year":"2021","journal-title":"Breast"},{"issue":"11","key":"10.1016\/j.semcancer.2025.05.009_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11113133","article-title":"Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients-a systematic review and meta-analysis","volume":"11","author":"Boszkiewicz","year":"2022","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib128","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000082","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circ. Genom. Precis Med."},{"key":"10.1016\/j.semcancer.2025.05.009_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104273","article-title":"A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: how to choose drugs appropriately?","volume":"196","author":"Zhen","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.05.009_bib130","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/CM9.0000000000003087","article-title":"Prevalence and risk evaluation of cardiovascular disease in the newly diagnosed prostate cancer population in China: a nationwide, multi-center, population-based cross-sectional study","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin. Med. J."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib131","doi-asserted-by":"crossref","first-page":"163","DOI":"10.6004\/jnccn.2022.7083","article-title":"Androgen deprivation therapy and risk of cardiovascular disease in patients with prostate cancer based on existence of cardiovascular risk","volume":"21","author":"Dragomir","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib132","doi-asserted-by":"crossref","first-page":"R589","DOI":"10.1152\/ajpregu.00259.2022","article-title":"Androgen-deprivation therapy with leuprolide increases abdominal adiposity without causing cardiac dysfunction in middle-aged male mice: effect of sildenafil","volume":"324","author":"Xi","year":"2023","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.05.009_bib133","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cam4.3016","article-title":"Metabolomic effects of androgen deprivation therapy treatment for prostate cancer","volume":"9","author":"Chi","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.semcancer.2025.05.009_bib134","article-title":"Endothelial dysfunction and diabetic cardiomyopathy","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib135","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1152\/ajpregu.00392.2014","article-title":"Reactive oxygen species: players in the cardiovascular effects of testosterone","volume":"310","author":"Tostes","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib136","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00365.2023","article-title":"NADPH oxidase 4-derived hydrogen peroxide counterbalances testosterone-induced endothelial dysfunction and migration","volume":"327","author":"Alves","year":"2024","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2025.05.009_bib137","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.semcancer.2024.10.004","article-title":"A systematic review of cardiovascular toxicities induced by cancer immune therapies: Underlying mechanisms, clinical manifestations and therapeutic approaches","volume":"106-107","author":"Liu","year":"2024","journal-title":"Semin Cancer Biol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib138","doi-asserted-by":"crossref","DOI":"10.1002\/cai2.140","article-title":"Breast cancer immunotherapy: realities and advances","volume":"3","author":"Medina","year":"2024","journal-title":"Cancer Innov."},{"issue":"48","key":"10.1016\/j.semcancer.2025.05.009_bib139","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib140","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur. J. Heart Fail"},{"issue":"12","key":"10.1016\/j.semcancer.2025.05.009_bib141","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib142","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol."},{"issue":"16","key":"10.1016\/j.semcancer.2025.05.009_bib143","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib144","doi-asserted-by":"crossref","DOI":"10.1007\/s00395-024-01092-8","article-title":"Changes in tumor and cardiac metabolism upon immune checkpoint","author":"Leven","year":"2024","journal-title":"Basic Res. Cardiol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.05.009_bib145","first-page":"662","article-title":"Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma","volume":"14","author":"K\u00e4hler","year":"2016","journal-title":"J. Dtsch Dermatol. Ges."},{"issue":"18","key":"10.1016\/j.semcancer.2025.05.009_bib146","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2025.05.009_bib147","doi-asserted-by":"crossref","DOI":"10.1007\/s00395-024-01068-8","article-title":"Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors","author":"Gergely","year":"2024","journal-title":"Basic Res. Cardiol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.05.009_bib148","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1007\/s11010-021-04219-w","article-title":"Role of PI3K\/Akt signaling pathway in cardiac fibrosis","volume":"476","author":"Qin","year":"2021","journal-title":"Mol. Cell Biochem"},{"key":"10.1016\/j.semcancer.2025.05.009_bib149","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.semcancer.2025.05.009_bib150","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.yjmcc.2020.09.009","article-title":"Glycogen synthase kinase-3\u03b2 inhibition alleviates activation of the NLRP3 inflammasome in myocardial infarction","volume":"149","author":"Wang","year":"2020","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174830","article-title":"GSK-3\u03b2-mediated activation of NLRP3 inflammasome leads to pyroptosis and apoptosis of rat cardiomyocytes and fibroblasts","volume":"920","author":"Wang","year":"2022","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.semcancer.2025.05.009_bib152","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.freeradbiomed.2021.12.001","article-title":"Nrf2 for protection against oxidant generation and mitochondrial damage in cardiac injury","volume":"179","author":"Chen","year":"2022","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib153","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/eurheartj\/ehab584","article-title":"Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments","volume":"43","author":"Varricchi","year":"2022","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib154","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.semcancer.2025.05.009_bib155","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021686","article-title":"Radiation-induced cardiovascular disease: review of an underrecognized pathology","volume":"10","author":"Belzile-Dugas","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib156","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7861\/clinmed.2021-0600","article-title":"Radiation-induced coronary artery disease: a difficult clinical conundrum","volume":"22","author":"Kirresh","year":"2022","journal-title":"Clin. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib157","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","article-title":"Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions","volume":"16","author":"Banfill","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib158","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12672-025-02046-9","article-title":"Simultaneous integrated dose reduction intensity-modulated radiotherapy improves survival in patients with locally advanced non-small cell lung cancer by reducing cardiac irradiation exposure","volume":"16","author":"Xu","year":"2025","journal-title":"Discov. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib159","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med."},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib160","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11912-022-01238-8","article-title":"Radiation-induced cardiovascular disease: mechanisms, prevention, and treatment","volume":"24","author":"Koutroumpakis","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib161","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/09553002.2021.1956007","article-title":"The cardiac toxicity of radiotherapy - a review of characteristics, mechanisms, diagnosis, and prevention","volume":"97","author":"Wei","year":"2021","journal-title":"Int J. Radiat. Biol."},{"issue":"16","key":"10.1016\/j.semcancer.2025.05.009_bib162","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib163","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","article-title":"PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes","volume":"13","author":"Du","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.05.009_bib164","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-022-01041-4","article-title":"New Insights into the Understanding of Mechanisms of Radiation-Induced Heart Disease","volume":"24","author":"Wang","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib166","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.trecan.2024.07.004","article-title":"Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights","volume":"10","author":"Lin","year":"2024","journal-title":"Trends Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2025.05.009_bib167","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11886-019-1192-y","article-title":"Radiation-associated pericardial disease","volume":"21","author":"Szpakowski","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib168","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1139\/cjpp-2017-0121","article-title":"Potential markers and metabolic processes involved in the mechanism of radiation-induced heart injury","volume":"95","author":"Slezak","year":"2017","journal-title":"Can. J. Physiol. Pharm."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib169","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/acs.jproteome.6b00795","article-title":"Role of TGF Beta and PPAR Alpha signaling pathways in radiation response of locally exposed heart: integrated global transcriptomics and proteomics analysis","volume":"16","author":"Subramanian","year":"2017","journal-title":"J. Proteome Res."},{"issue":"18","key":"10.1016\/j.semcancer.2025.05.009_bib170","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016875","article-title":"Metabolic changes precede radiation-induced cardiac remodeling in beagles: using noninvasive 18F-FDG (18F-Fludeoxyglucose) and 13N-ammonia positron emission tomography\/computed tomography scans","volume":"9","author":"Yan","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib171","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jrr\/rrz079","article-title":"Metabolic changes in mice cardiac tissue after low-dose irradiation revealed by 1H NMR spectroscopy","volume":"61","author":"Gramatyka","year":"2020","journal-title":"J. Radiat. Res."},{"issue":"21","key":"10.1016\/j.semcancer.2025.05.009_bib172","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2012.5502","article-title":"Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery","volume":"307","author":"Devereaux","year":"2012","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.semcancer.2025.05.009_bib173","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1161\/CIR.0000000000001285","article-title":"2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"150","author":"Thompson","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib174","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jamacardio.2016.4792","article-title":"Perioperative major adverse cardiovascular and cerebrovascular events associated with noncardiac surgery","volume":"2","author":"Smilowitz","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.05.009_bib175","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/anae.16220","article-title":"Impact of postoperative cardiovascular complications on 30-day mortality after major abdominal surgery: an international prospective cohort study","volume":"79","author":"Collaborative","year":"2024","journal-title":"Anaesthesia"},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib176","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/bjs.11128","article-title":"Meta-analysis of risk factors and complications associated with atrial fibrillation after oesophagectomy","volume":"106","author":"Schizas","year":"2019","journal-title":"Br. J. Surg."},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib177","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s11883-012-0284-6","article-title":"The effect of gastrointestinal surgery on insulin resistance and insulin secretion","volume":"14","author":"Castagneto","year":"2012","journal-title":"Curr. Atheroscler. Rep."},{"issue":"13","key":"10.1016\/j.semcancer.2025.05.009_bib178","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2174\/0929867324666170616105639","article-title":"The influence of obese insulin-resistance on the outcome of the ischemia\/reperfusion insult to the heart","volume":"25","author":"Shinlapawittayatorn","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.semcancer.2025.05.009_bib179","doi-asserted-by":"crossref","DOI":"10.1177\/2050312120965752","article-title":"Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer","volume":"8","author":"Amin","year":"2020","journal-title":"SAGE Open Med."},{"issue":"21","key":"10.1016\/j.semcancer.2025.05.009_bib180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112906","article-title":"The role of inflammation in cardiovascular disease","volume":"23","author":"Henein","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1185","key":"10.1016\/j.semcancer.2025.05.009_bib181","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/postmj\/qgae017","article-title":"Genetic effects of inflammatory cytokines on coronary artery disease and myocardial infarction and the mediating roles of lipid traits","volume":"100","author":"Liu","year":"2024","journal-title":"Post. Med. J."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib182","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102150","article-title":"Hypothalamic-pituitary-adrenal axis modulation of glucocorticoids in the cardiovascular system","volume":"18","author":"Burford","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib183","first-page":"322","article-title":"The glutamine debate in surgery and critical care","volume":"25","author":"Wischmeyer","year":"2019","journal-title":"Curr. Opin. Crit. Care"},{"issue":"8","key":"10.1016\/j.semcancer.2025.05.009_bib184","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jjco\/hyx068","article-title":"Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients","volume":"47","author":"Tajiri","year":"2017","journal-title":"Jpn J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11912-019-0796-0","article-title":"Cardiovascular disease and cancer: is there increasing overlap?","volume":"21","author":"Vincent","year":"2019","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"10.1016\/j.semcancer.2025.05.009_bib186","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail"},{"issue":"17","key":"10.1016\/j.semcancer.2025.05.009_bib187","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.05.009_bib188","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail"},{"issue":"7","key":"10.1016\/j.semcancer.2025.05.009_bib189","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11864-019-0658-x","article-title":"Pediatric cardio-oncology: development of cancer treatment-related cardiotoxicity and the therapeutic approach to affected patients","volume":"20","author":"Ryan","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fcvm.2020.00035","article-title":"Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer?","volume":"7","author":"Murabito","year":"2020","journal-title":"Front. Cardiovasc Med."},{"issue":"8","key":"10.1016\/j.semcancer.2025.05.009_bib191","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1002\/tox.24291","article-title":"Betaine ameliorates doxorubicin-induced cardiomyopathy by inhibiting oxidative stress, inflammation, and fibrosis through the modulation of AMPK\/Nrf2\/TGF-\u03b2 expression","volume":"39","author":"Singh","year":"2024","journal-title":"Environ. Toxicol."},{"issue":"Pt 2","key":"10.1016\/j.semcancer.2025.05.009_bib192","article-title":"Protection against cancer therapy-induced cardiovascular injury by planed-derived polyphenols and nanomaterials","volume":"238","author":"Liao","year":"2023","journal-title":"Environ. Res."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib193","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bbrc.2013.10.063","article-title":"Cationic antioxidants as a powerful tool against mitochondrial oxidative stress","volume":"441","author":"Skulachev","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib194","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.bpj.2008.10.042","article-title":"Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q","volume":"96","author":"Chandran","year":"2009","journal-title":"Biophys. J."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib195","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3109\/13880209.2015.1070879","article-title":"Ameliorative effect of naringin against doxorubicin-induced acute cardiac toxicity in rats","volume":"54","author":"Kwatra","year":"2016","journal-title":"Pharm. Biol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.05.009_bib196","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1073\/pnas.1821022116","article-title":"Ferroptosis as a target for protection against cardiomyopathy","volume":"116","author":"Fang","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib197","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2025.05.009_bib198","article-title":"Protective effects of dexazoxane on rat ferroptosis in doxorubicin-induced cardiomyopathy through regulating HMGB1","volume":"8","author":"Zhang","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.semcancer.2025.05.009_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109241","article-title":"Resveratrol alleviated 5-FU-induced cardiotoxicity by attenuating GPX4 dependent ferroptosis","volume":"112","author":"Li","year":"2023","journal-title":"J. Nutr. Biochem."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib200","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1039\/D2FO03331C","article-title":"Berberine hydrochloride alleviates imatinib mesylate - induced cardiotoxicity through the inhibition of Nrf2-dependent ferroptosis","volume":"14","author":"Song","year":"2023","journal-title":"Food Funct."},{"key":"10.1016\/j.semcancer.2025.05.009_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104846","article-title":"Mitophagy inhibitor liensinine suppresses doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated maladaptive mitochondrial fission","volume":"157","author":"Liang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.semcancer.2025.05.009_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.153964","article-title":"Salidroside inhibits doxorubicin-induced cardiomyopathy by modulating a ferroptosis-dependent pathway","volume":"99","author":"Chen","year":"2022","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib203","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00567.2008","article-title":"Injection of isolated mitochondria during early reperfusion for cardioprotection","volume":"296","author":"McCully","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120701","article-title":"Mitotherapy in doxorubicin induced cardiotoxicity: a promising strategy to reduce the complications of treatment","volume":"304","author":"Maleki","year":"2022","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib205","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jtcvs.2017.02.018","article-title":"Autologous mitochondrial transplantation for dysfunction after ischemia-reperfusion injury","volume":"154","author":"Emani","year":"2017","journal-title":"J. Thorac. Cardiovasc Surg."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib206","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib207","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/heartjnl-2022-321545","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer","volume":"109","author":"Chiang","year":"2023","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib208","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.neo.2021.02.003","article-title":"Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin","volume":"23","author":"Papadopoli","year":"2021","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.semcancer.2025.05.009_bib209","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.119.040144","article-title":"Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 Trial","volume":"140","author":"Bergmark","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib210","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1016\/j.apsb.2023.03.019","article-title":"Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling","volume":"13","author":"Peng","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib211","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00109-013-1064-7","article-title":"Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension","volume":"91","author":"Piao","year":"2013","journal-title":"J. Mol. Med."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib212","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11912-024-01579-6","article-title":"Statins for the primary prevention of anthracycline cardiotoxicity: a comprehensive review","volume":"26","author":"Bhasin","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"9","key":"10.1016\/j.semcancer.2025.05.009_bib213","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid."},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib214","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","volume":"9","author":"Thavendiranathan","year":"2023","journal-title":"Eur. Heart J. Cardiovasc Pharm."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00280-009-1165-8","article-title":"Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats","volume":"66","author":"Todorova","year":"2010","journal-title":"Cancer Chemother. Pharm."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib216","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3945\/jn.109.113415","article-title":"Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats","volume":"140","author":"Todorova","year":"2010","journal-title":"J. Nutr."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib217","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/jsre.1999.5677","article-title":"Glutamine protects against doxorubicin-induced cardiotoxicity","volume":"85","author":"Cao","year":"1999","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.semcancer.2025.05.009_bib218","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3389\/fphys.2017.01042","article-title":"Increased dietary leucine reduces doxorubicin-associated cardiac dysfunction in rats","volume":"8","author":"Fidale","year":"2017","journal-title":"Front. Physiol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib219","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12012-023-09817-2","article-title":"Cardioprotective effects of leucine supplementation against doxorubicin-induced cardiotoxicit","volume":"24","author":"Guimar\u00e3es","year":"2024","journal-title":"Cardiovasc. Toxicol."},{"issue":"9","key":"10.1016\/j.semcancer.2025.05.009_bib220","doi-asserted-by":"crossref","DOI":"10.3390\/life13091823","article-title":"Effects of an L-leucine-rich diet on liver and kidneys in a doxorubicin toxicity model","volume":"13","author":"Duarte","year":"2023","journal-title":"Life"},{"issue":"18","key":"10.1016\/j.semcancer.2025.05.009_bib221","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","article-title":"Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients","volume":"139","author":"Nielsen","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib222","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23041","article-title":"Antiapoptotic and anti-inflammatory effects of Ppar\u03b3 agonist, pioglitazone, reversed Dox-induced cardiotoxicity through mediating of miR-130a downregulation in C57BL\/6 mice","volume":"36","author":"Pakravan","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib223","first-page":"12216","article-title":"Effects of PPAR\u03b1\/PGC-1\u03b1 on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in vitro","volume":"8","author":"Yang","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.semcancer.2025.05.009_bib224","doi-asserted-by":"crossref","DOI":"10.1177\/15347354241291176","article-title":"Effects of physical activity on cardiotoxicity and cardio respiratory function in cancer survivors undergoing chemotherapy: a systematic review and meta-analysis","volume":"23","author":"Chen","year":"2024","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.semcancer.2025.05.009_bib225","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072003","article-title":"Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis","volume":"380","author":"Karam","year":"2023","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib226","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00394-020-02346-6","article-title":"An updated systematic review and meta-analysis on adherence to mediterranean diet and risk of cancer","volume":"60","author":"Morze","year":"2021","journal-title":"Eur. J. Nutr."},{"issue":"14","key":"10.1016\/j.semcancer.2025.05.009_bib227","first-page":"1388","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"379","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7884","key":"10.1016\/j.semcancer.2025.05.009_bib228","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41586-021-04049-2","article-title":"Low glycaemic diets alter lipid metabolism to influence tumour growth","volume":"599","author":"Lien","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib229","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000515960","article-title":"Time-restricted feeding restored insulin-growth hormone balance and improved substrate and energy metabolism in MC4RKO obese mice","volume":"112","author":"Wang","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib230","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41467-020-20743-7","article-title":"Time-restricted feeding normalizes hyperinsulinemia to inhibit breast cancer in obese postmenopausal mouse models","volume":"12","author":"Das","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.05.009_bib231","article-title":"Can dietary nutrients prevent cancer chemotherapy-induced cardiotoxicity? an evidence mapping of human studies and animal models","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"21","key":"10.1016\/j.semcancer.2025.05.009_bib232","doi-asserted-by":"crossref","DOI":"10.3390\/nu16213777","article-title":"Nutrition modulation of cardiotoxicity in breast cancer: a scoping review","volume":"16","author":"Stephenson","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.semcancer.2025.05.009_bib233","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijnurstu.2024.104983","article-title":"Effects of behavioural activation on psychological distress among people with cancer: A systematic review and meta-analysis","volume":"164","author":"Wei","year":"2025","journal-title":"Int. J. Nurs. Stud."},{"key":"10.1016\/j.semcancer.2025.05.009_bib234","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.942219","article-title":"Quality assessment of clinical practice guidelines on psychological distress of cancer patients using the AGREE II instrument","volume":"12","author":"Hao","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.05.009_bib235","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s11845-023-03318-5","article-title":"Anxiety and depression during 3-year follow-up period in postoperative gastrointestinal cancer patients: prevalence, vertical change, risk factors, and prognostic value","volume":"192","author":"Li","year":"2023","journal-title":"Ir. J. Med. Sci."},{"issue":"18","key":"10.1016\/j.semcancer.2025.05.009_bib236","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/eurheartj\/ehad188","article-title":"Psychological therapies for depression and cardiovascular risk: evidence from national healthcare records in England","volume":"44","author":"El Baou","year":"2023","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.semcancer.2025.05.009_bib237","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/eurheartj\/ehad173","article-title":"Successful psychological treatment of depression and subsequent reduction in CVD events","volume":"44","author":"Hare","year":"2023","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib238","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11936-019-0724-5","article-title":"Psychosocial stress and cardiovascular disease","volume":"21","author":"Dar","year":"2019","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib239","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.mayocp.2022.02.004","article-title":"Mental stress and its effects on vascular health","volume":"97","author":"Sara","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.semcancer.2025.05.009_bib240","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neubiorev.2020.06.031","article-title":"Advances in understanding mechanisms and therapeutic targets to treat comorbid depression and cardiovascular disease","volume":"116","author":"Pope","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib241","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/hm.HM-D-22-00002","article-title":"A narrative review on mental stress and cardiovascular disease: evidence, mechanisms, and potential interventions","volume":"7","author":"Gill","year":"2023","journal-title":"Heart Mind"},{"issue":"23","key":"10.1016\/j.semcancer.2025.05.009_bib242","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1111\/bph.13010","article-title":"Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases","volume":"172","author":"He","year":"2015","journal-title":"Br. J. Pharm."},{"issue":"7","key":"10.1016\/j.semcancer.2025.05.009_bib243","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2174\/1570159X14666151208113700","article-title":"Inflammation in depression and the potential for anti-inflammatory treatment","volume":"14","author":"Kohler","year":"2016","journal-title":"Curr. Neuropharmacol."},{"issue":"10","key":"10.1016\/j.semcancer.2025.05.009_bib244","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.002218","article-title":"Meditation and cardiovascular risk reduction: a scientific statement from the american heart association","volume":"6","author":"Levine","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib245","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.imr.2019.11.002","article-title":"Buddhist meditation for vascular function: a narrative review","volume":"8","author":"Amarasekera","year":"2019","journal-title":"Integr. Med. Res."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib246","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12872-024-03830-1","article-title":"Association of greenspaces exposure with cardiometabolic risk factors: a systematic review and meta-analysis","volume":"24","author":"Sharifi","year":"2024","journal-title":"BMC Cardiovasc. Disord."},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib247","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1007\/s11033-023-08318-3","article-title":"Mitochondria-targeted combination treatment strategy counteracts myocardial reperfusion injury of aged rats by modulating autophagy and inflammatory response","volume":"50","author":"Mokhtari","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"22","key":"10.1016\/j.semcancer.2025.05.009_bib248","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-oncology services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib249","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ejhf.3102","article-title":"European society of cardiology core curriculum for cardio-oncology","volume":"26","author":"L\u00f3pez-Fern\u00e1ndez","year":"2024","journal-title":"Eur. J. Heart Fail"},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib250","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/cge.14452","article-title":"Association between genetic variants of transmembrane transporters and susceptibility to anthracycline-induced cardiotoxicity: current understanding and existing evidence","volume":"105","author":"Ni","year":"2024","journal-title":"Clin. Genet"},{"issue":"13","key":"10.1016\/j.semcancer.2025.05.009_bib251","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib252","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bcp.13008","article-title":"Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity","volume":"82","author":"Aminkeng","year":"2016","journal-title":"Br. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib253","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1186\/s12967-024-05537-5","article-title":"Genetic factors in the pathogenesis of cardio-oncology","volume":"22","author":"Qi","year":"2024","journal-title":"J. Transl. Med."},{"issue":"17","key":"10.1016\/j.semcancer.2025.05.009_bib254","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1002\/cncr.32948","article-title":"Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A Children's Oncology Group ALTE03N1 report","volume":"126","author":"Singh","year":"2020","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib255","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaccao.2020.09.006","article-title":"Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology State-of-the-Art review","volume":"2","author":"Bhatia","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib256","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib257","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/RES.0000000000000473","article-title":"Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the american heart association","volume":"129","author":"Asnani","year":"2021","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.semcancer.2025.05.009_bib258","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-021-06427-w","article-title":"Trastuzumab does not bind rat or mouse ErbB2\/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics","volume":"191","author":"Lewis Phillips","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.semcancer.2025.05.009_bib259","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1158\/0008-5472.CAN-03-2962","article-title":"Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2\/neu transgenic mice","volume":"64","author":"Quaglino","year":"2004","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.semcancer.2025.05.009_bib260","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","article-title":"Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer","volume":"139","author":"Kitani","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.semcancer.2025.05.009_bib261","author":"Ghigo","year":"2025","journal-title":"Eur. J. Heart Fail"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib262","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jbt.21740","article-title":"Thymol and carvacrol prevent doxorubicin-induced cardiotoxicity by abrogation of oxidative stress, inflammation, and apoptosis in rats","volume":"30","author":"El-Sayed","year":"2016","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.05.009_bib263","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1039\/C8FO00466H","article-title":"Curcumin attenuates doxorubicin-induced cardiotoxicity via suppressing oxidative stress and preventing mitochondrial dysfunction mediated by 14-3-3\u03b3","volume":"9","author":"He","year":"2018","journal-title":"Food Funct."},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib264","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/15376516.2018.1564948","article-title":"Quercetin protects cardiomyocytes against doxorubicin-induced toxicity by suppressing oxidative stress and improving mitochondrial function via 14-3-3\u03b3","volume":"29","author":"Chen","year":"2019","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.semcancer.2025.05.009_bib265","article-title":"Sunitinib and Imatinib display differential cardiotoxicity in adult rat cardiac fibroblasts that involves a role for calcium\/calmodulin dependent Protein Kinase II","volume":"7","author":"McMullen","year":"2020","journal-title":"Front. Cardiovasc Med."},{"key":"10.1016\/j.semcancer.2025.05.009_bib266","article-title":"Fisetin Attenuates doxorubicin-induced cardiomyopathy in vivo and in vitro by inhibiting ferroptosis through SIRT1\/Nrf2 signaling pathway activation","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharm."},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib267","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11033-018-4450-y","article-title":"Fisetin, a plant flavonoid ameliorates doxorubicin-induced cardiotoxicity in experimental rats: the decisive role of caspase-3, COX-II, cTn-I, iNOs and TNF-\u03b1","volume":"46","author":"Ma","year":"2019","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib268","doi-asserted-by":"crossref","first-page":"9145","DOI":"10.1080\/21655979.2022.2036895","article-title":"Propofol protects cardiomyocytes from doxorubicin-induced toxic injury by activating the nuclear factor erythroid 2-related factor 2\/glutathione peroxidase 4 signaling pathways","volume":"13","author":"Lu","year":"2022","journal-title":"Bioengineered"},{"issue":"1","key":"10.1016\/j.semcancer.2025.05.009_bib269","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1186\/s12967-023-04715-1","article-title":"WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis","volume":"21","author":"Tai","year":"2023","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.semcancer.2025.05.009_bib270","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41419-020-02948-2","article-title":"Acyl-CoA thioesterase 1 prevents cardiomyocytes from Doxorubicin-induced ferroptosis via shaping the lipid composition","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2025.05.009_bib271","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2020.152508","article-title":"Glycyrrhizin improved autophagy flux via HMGB1-dependent Akt\/mTOR signaling pathway to prevent Doxorubicin-induced cardiotoxicity","volume":"441","author":"Lv","year":"2020","journal-title":"Toxicology"},{"key":"10.1016\/j.semcancer.2025.05.009_bib272","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116713","article-title":"Angiotensin IV ameliorates doxorubicin-induced cardiotoxicity by increasing glutathione peroxidase 4 and alleviating ferroptosis","volume":"479","author":"Yang","year":"2023","journal-title":"Toxicol. Appl. Pharm."},{"issue":"Pt 1","key":"10.1016\/j.semcancer.2025.05.009_bib273","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.freeradbiomed.2022.10.268","article-title":"Exosomal thioredoxin-1 from hypoxic human umbilical cord mesenchymal stem cells inhibits ferroptosis in doxorubicin-induced cardiotoxicity via mTORC1 signaling","volume":"193","author":"Yu","year":"2022","journal-title":"Free Radic. Biol. Med."},{"issue":"9","key":"10.1016\/j.semcancer.2025.05.009_bib274","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1111\/jcmm.14466","article-title":"Yellow wine polyphenolic compounds prevents doxorubicin-induced cardiotoxicity through activation of the Nrf2 signalling pathway","volume":"23","author":"Lin","year":"2019","journal-title":"J. Cell Mol. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib275","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00280-017-3413-7","article-title":"Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis","volume":"80","author":"Abdel-Daim","year":"2017","journal-title":"Cancer Chemother. Pharm."},{"issue":"2-3","key":"10.1016\/j.semcancer.2025.05.009_bib276","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tox.2005.10.015","article-title":"Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity","volume":"218","author":"Yilmaz","year":"2006","journal-title":"Toxicology"},{"issue":"7","key":"10.1016\/j.semcancer.2025.05.009_bib277","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12012-021-09644-3","article-title":"Chia seed oil ameliorates doxorubicin-induced cardiotoxicity in female wistar rats: an electrocardiographic, biochemical and histopathological approach","volume":"21","author":"Ahmed","year":"2021","journal-title":"Cardiovasc Toxicol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.05.009_bib278","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tice.2017.03.007","article-title":"Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity","volume":"49","author":"Mustafa","year":"2017","journal-title":"Tissue Cell"},{"issue":"5","key":"10.1016\/j.semcancer.2025.05.009_bib279","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/13510002.1996.11747068","article-title":"Selenium supplementation decreases the pro-oxidant and cardiotoxicity effects of adriamycin in the rat","volume":"2","author":"Coudray","year":"1996","journal-title":"Redox Rep."},{"issue":"4","key":"10.1016\/j.semcancer.2025.05.009_bib280","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clbc.2022.01.008","article-title":"The cardioprotective effect of Vitamin D in breast cancer patients receiving adjuvant doxorubicin based chemotherapy","volume":"22","author":"El-Bassiouny","year":"2022","journal-title":"Clin. Breast Cancer"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:48:16Z","timestamp":1762354096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X25000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":280,"alternative-id":["S1044579X25000719"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.05.009","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic reprogramming in cancer therapy-related cardiovascular toxicity: Mechanisms and intervention strategies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}